Thu: Teva sets seal on negative week

TASE
TASE

The Tel Aviv 25 Index fell again today, making it a 2% drop this week, with Teva leading the slide, following reports that chairman Phillip Frost wants fewer directors.

The Tel Aviv Stock Exchange (TASE) fell today. The Tel Aviv 25 Index fell 0.71% to 1,322.02 points, the Tel Aviv 100 Index fell 0.64% to 1,219.85 points, but the BlueTech 50 Index rose 0.13% to 358.38 points. Turnover was NIS 1.13 billion.

The TASE fell today, in line with losses on European markets and at the opening on Wall Street. The Tel Aviv 25 Index fell 2% for the week.

In the foreign currency market, the Bank of Israel set the shekel-dollar representative exchange rate at NIS 3.486/$, down 0.11% on yesterday's rate, and set the shekel-euro exchange rate at NIS 4.755/€, up 0.49%.

In the bond market, both long-term Shahar unlinked shekel government bonds and long term Galil CPI-linked government rose strongly. The corporate bond benchmark Tel-Bond 20 Index rose 0.20%.

In the stock market, Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) fell 2%, for the biggest loss among Tel Aviv 25 shares, and on the day's biggest turnover of NIS 63.9 million, following reports that chairman Phillip Frost is planning to reduce the number of seats on its board of directors. Partner Communications Ltd. (Nasdaq: PTNR; TASE: PTNR) rose 0.7%, for the biggest gain among Tel Aviv 25 shares.

On the Tel Aviv 100 Index, Ormat Industries Ltd. (TASE: ORMT) fell 2.1%, after Barclays Capital downgraded its recommendation for the share to "Underweight." Mazor Robotics Ltd. (Nasdaq: MZOR; TASE:MZOR) fell 2.8%, even though Barclay's raised its target price for the share. Silicom Ltd. (Nasdaq:SILC; TASE:SILC) jumped 27.5%, after publishing record fourth quarter and full-year results for 2013.

In the life sciences, Bio-Light Israeli Life Sciences Investments Ltd. (TASE:BOLT; Bulletin Board: BLGTY) rose 2.5%, after listing its shares on Wall Street today, and BiolineRX Ltd. (Nasdaq: BLRX); TASE:BLRX) rose 3.6%, after obtaining US Food and Drug Administration (FDA) orphan drug status for its drug, BL-8040 as a treatment for stem cell mobilization.

Published by Globes [online], Israel business news - www.globes-online.com - on January 23, 2014

© Copyright of Globes Publisher Itonut (1983) Ltd. 2014

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018